SCHEMBL3069737

SCHEMBL3069737

Fc1cccc(C(c2cccnc2)c2c[nH]cn2)c1Cl

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 2/20 0.40
KCNA5 P22460 7/20 0.38
SLC6A2 P23975 3/20 0.37
SLC6A4 P31645 3/20 0.37
SLC6A3 Q01959 3/20 0.37
CFTR P13569 1/20 0.37
GOPC Q9HD26 1/20 0.37
KCND3 Q9UK17 1/20 0.35
GAA P10253 1/20 0.32
P2RX7 Q99572 2/20 0.31
NPC1 O15118 1/20 0.31
ALDH1A1 P00352 1/20 0.31
MAPK1 P28482 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
CYP2D6 P10635 1/20 0.31
KCNH2 Q12809 1/20 0.31
CYP3A4 P08684 1/20 0.30
CYP3A5 P20815 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13089104 0.88 KCNA5 (0.45) CYP19A1KCNA5SLC6A2SLC6A4SLC6A3
SCHEMBL13089119 0.88 SLC6A2 (0.39) CYP19A1KCNA5SLC6A2SLC6A4SLC6A3
SCHEMBL13089152 0.88 SLC6A2 (0.44) CYP19A1KCNA5SLC6A2SLC6A4SLC6A3
SCHEMBL13089100 0.79 IDO1 (0.38) CYP19A1KCNA5SLC6A2SLC6A4SLC6A3
SCHEMBL13089094 0.78 GAA (0.44) CYP19A1KCNA5SLC6A2SLC6A4SLC6A3
SCHEMBL13089142 0.78 GAA (0.52) CYP19A1KCNA5SLC6A2SLC6A4SLC6A3
SCHEMBL13089168 0.78 CFTR (0.41) CYP19A1KCNA5SLC6A2SLC6A4SLC6A3
SCHEMBL3028121 0.77 CFTR (0.38) CYP19A1KCNA5SLC6A2SLC6A4SLC6A3
SCHEMBL13089180 0.76 SLC6A2 (0.61) CYP19A1KCNA5SLC6A2SLC6A4SLC6A3
SCHEMBL13089064 0.75 SLC6A2 (0.41) CYP19A1KCNA5SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155715-B1 ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS ALLERGAN INC (US) 2013-03-13 EP disclosed
US-20100273814-A1 ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS SINHA SANTOSH C 2010-10-28 US disclosed
US-20100273814-A1 ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS SINHA SANTOSH C 2010-10-28 US disclosed
US-20100273814-A1 ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS SINHA SANTOSH C 2010-10-28 US disclosed
EP-2155715-A1 ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS ALLERGAN, INC. (US) 2010-02-24 EP disclosed
WO-2008141312-A1 ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS ALLERGAN, INC. (US) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273814-A1 ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS CYP11B2, TPMT, COXFA4L2 CYP19A1 485/4885KCNA5 3273/4885SLC6A2 2046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.